A Sjogrens trial of ianalumab (in Phase III) announced reaching primary endpoints. Ianalumab is a B-cell depletion and BAFF-R inhibition treatment. Ianalumab has the potential to become the first and only targeted treatment for Sjogrens, once its approved.
www.novartis.com/news/media-r...
novartis.com
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
![Figure 4 from the @wecrunchme first report titled "The Future is a Policy Choice". The figure is titled: "Figure 4: US Disease burden of selected diseases [36]. The left y-axis is titled "DALYS". The x-axis has the names of selected diseases, Multiple Sclerosis, IBD, Rheumatoid Arthritis, Parkinson's Disease, ME/CFS, Asthma, Kidney Disease, Diabetes, Long COVID". Inset in the figure, "The estimated disease burden of Long Covid is comparable to diabetes". Above each disease is a vertical bar that indicates the number of DALYS, with diabetes and Long COVID having the same number of DALYS, which are greater than any other listed disease.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:mjmkbp2ueuant5m5vrpsgkyq/bafkreihjiz5jzsnegltosy5gfelamxlgjluqgvqhzmiclnoffilfh7eehu)
